8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Feb 5, 2026·SEC
Strata Critical Medical, Inc.(SRTA)Earnings, Financials & Key Ratios
SRTA•NASDAQ
$5.30
10.6× P/E·Price updated Jun 27, 2026
AboutStrata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.Show more
- Revenue$197M-20.7%
- EBITDA-$14M+49.3%
- Net Income$41M+251.4%
- EPS (Diluted)0.50+242.9%
- Gross Margin20.86%-11.9%
- EBITDA Margin-7.19%+36.1%
- Operating Margin-11.34%+16.9%
- Net Margin20.97%+291.0%
- ROE16.51%+237.9%
SRTA Price & Volume
Strata Critical Medical, Inc. (SRTA) stock price & volume — 10-year historical chart
Loading chart...
Volatile Revenue Growth Masks Persistent Operating Losses
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Healthy
Cash Flow:Burning
Primary Risk:Persistent Operating Cash Burn
"Strata Critical Medical is currently navigating a high-risk strategic pivot toward specialized medical logistics, characterized by erratic top-line performance and a reliance on non-recurring items to bolster net income. While the company maintains a conservative capital structure with a debt-to-equity ratio of 0.02, the inability to achieve consistent positive free cash flow remains a significant concern for long-term sustainability. Investors should monitor whether the recent 24.1% revenue growth in 2026Q1 can be sustained without further eroding the company's already thin 21.0% gross margins."
Verdict Logic
the company's inability to generate consistent free cash flow, highlighted by a -70.9% FCF margin in 2025Q3, suggests that the current business model is not yet self-sustaining despite a healthy $58.7M cash balance.
SRTA Growth Metrics
Strata Critical Medical, Inc. (SRTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years53.1%
3 Years10.5%
TTM-16.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM276.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.46%
Return on Capital
10 Years-12.78%
5 Years-15.62%
3 Years-15.49%
Last Year-8.28%
SRTA Recent Earnings
Strata Critical Medical, Inc. (SRTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.03+175.0%
$0.04
Rev
$67M+5.8%
$64M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.06-721.4%
$0.01
Rev
$67M+10.7%
$60M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.06-200.0%
$0.02
Rev
$49M-18.3%
$60M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.05-25.0%
$0.04
Rev
$71M-11.4%
$80M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.03vs $0.04+175.0% | $67Mvs $64M+5.8% |
| Q2 2026 | Mar 3, 2026 | $0.06vs $0.01-721.4% | $67Mvs $60M+10.7% |
| Q4 2025 | Nov 10, 2025 | $0.06vs $0.02-200.0% | $49Mvs $60M-18.3% |
| Q3 2025 | Aug 5, 2025 | $0.05vs $0.04-25.0% | $71Mvs $80M-11.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Strata Critical Medical, Inc. (SRTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.30 | $458.59M | 10.60 | -20.73% | 20.97% | 16.51% | — | |
| $163.05 | $9.52B | 27.92 | 18.72% | 6.89% | 16.61% | — | |
| $96.95 | $1.81B | 18.61 | 23.21% | 6.89% | 9.34% | — | |
| $13.22 | $427.44M | -4.51 | -21.56% | -9.84% | -27.1% | — | |
| $32.76 | $1.27B | -13.21 | -8.49% | -0.95% | -4.98% | — | |
| $6.99 | $212.22M | -4.34 | 3.1% | -4.29% | -18.74% | — |
Compare SRTA vs Peers
Strata Critical Medical, Inc. (SRTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRTA SEC Filings & Documents
Strata Critical Medical, Inc. (SRTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SRTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SRTA Frequently Asked Questions
Strata Critical Medical, Inc. (SRTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Strata Critical Medical, Inc.'s revenue?
Strata Critical Medical, Inc. (SRTA) reported $210.2M in revenue for fiscal year 2025. This represents a 574% increase from $31.2M in 2019.
How fast is Strata Critical Medical, Inc. growing?
Strata Critical Medical, Inc. (SRTA) saw revenue decline by 20.7% over the past year.
Is SRTA profitable?
Yes, Strata Critical Medical, Inc. (SRTA) is profitable, generating $47.0M in net income for fiscal year 2025 (21.0% net margin).
Dividend & Returns
What is SRTA's return on equity?
Strata Critical Medical, Inc. (SRTA) has a return on equity (ROE) of 16.5%. This is reasonable for most industries.
What is Strata Critical Medical, Inc.'s free cash flow?
Strata Critical Medical, Inc. (SRTA) had negative free cash flow of $54.0M in fiscal year 2025, likely due to heavy capital investments.